All In Biotech

Free tool

FAERS Monitor: Tecentriq Hybreza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761347 or its brand name (Tecentriq Hybreza, Atezolizumab and Hyaluronidase-Tqjs). Reports on generic versions are filed under their own applications.

Reports

24

Serious

5

21% of reports

Hospitalization

1

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain4
  • no adverse event4
  • blister2
  • malaise2
  • pain2
  • product administered at inappropriate site2
  • product storage error2
  • abdominal discomfort1
  • burning sensation1
  • death1
  • deep vein thrombosis1
  • dizziness1
  • dyspnoea1
  • fatigue1
  • flushing1

Reports by year received

View as table
YearReports
20244
202510
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,135 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product administered at inappropriate site295.625.4105
blister231.28.332
product storage error220.05.320
no adverse eventSignal419.37.953
deep vein thrombosis113.52.02
burning sensation112.51.82
injection site painSignal411.44.729
flushing18.61.31
abdominal discomfort15.20.81
malaise24.01.12
pain22.90.81
dizziness11.80.30
dyspnoea11.50.20
fatigue11.10.20
death11.00.10

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.